GMAB

Genmab ADR

40.06

Oct 22 • 12:14 PM ET +0.49 (1.23%)

Healthcare Biotechnology Denmark Large NASD

Peers: BNTX INCY REGN SMMT ONC EXEL ARGX HALO JAZZ ASND

| Held by: IBB FBT AVDE CANC FTQI LOEV APIE ONEQ AADR AVIV

Index	-
Market Cap	23.94B
Enterprise Value	27.71B
Income	785.93M
Sales	4.13B
Book/sh	9.98
Cash/sh	2.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3029
IPO	Jun 01, 2009

P/E	31.72
Forward P/E	23.16
PEG	1.14
P/S	5.80
P/B	4.01
P/C	15.93
P/FCF	27.51
EV/EBITDA	19.43
EV/Sales	6.71
Quick Ratio	2.44
Current Ratio	2.46
Debt/Eq	0.89
LT Debt/Eq	0.83
Option/Short	Yes / Yes

EPS (ttm)	1.26
EPS next Y	1.73
EPS next Q	0.35
EPS this Y	-23.00%
EPS next Y	46.16%
EPS next 5Y	20.38%
EPS past 3/5Y	9.68% 6.84%
Sales past 3/5Y	22.11% 19.27%
EPS Y/Y TTM	-36.69%
Sales Y/Y TTM	21.75%
EPS Q/Q	-11.45%
Sales Q/Q	23.03%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	37.92% 3.46%

Insider Own	1.75%
Insider Trans	0.00%
Inst Own	18.59%
Inst Trans	0.25%
ROA	8.28%
ROE	13.96%
ROIC	7.20%
Gross Margin	93.03%
Oper. Margin	32.27%
Profit Margin	19.04%
SMA20	8.25%
SMA50	14.55%
SMA200	33.49%
Trades

Shs Outstand	597.02M
Shs Float	587.09M
Short Float	1.03%
Short Ratio	2.05
Short Interest	6.06M
52W High	40.17 -0.28%
52W Low	23.62 69.60%
Volatility	2.98% 3.56%
ATR (14)	1.19
RSI (14)	68.98
Beta	0.83
Rel Volume	1.25
Avg Volume	2.95M
Volume	1,665,126

Perf Week	5.92%
Perf Month	15.28%
Perf Quarter	38.75%
Perf Half Y	48.47%
Perf YTD	30.06%
Perf Year	33.89%
Perf 3Y	34.24%
Perf 5Y	-14.28%
Perf 10Y	140.84%
Recom	1.36
Target Price	44.23
Prev Close	39.57
Price	40.06
Change %	1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-26	Upgrade	TD Cowen	Hold → Buy	$43
May-27-26	Initiated	Truist	Buy	$40
Apr-22-26	Upgrade	Goldman	Neutral → Buy
Mar-27-26	Initiated	Wolfe Research	Outperform	$32
Mar-02-26	Initiated	Wells Fargo	Overweight	$40
Feb-17-26	Resumed	Morgan Stanley	Equal-Weight	$34
Feb-17-26	Resumed	Jefferies	Buy	$41.50
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy	$43
Apr-01-25	Downgrade	Bernstein	Mkt Perform → Underperform
Mar-11-25	Upgrade	William Blair	Mkt Perform → Outperform
Feb-13-25	Upgrade	Leerink Partners	Market Perform → Outperform	$27
Oct-08-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Resumed	Morgan Stanley	Equal-Weight	$31
Aug-20-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-15-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-23-24	Upgrade	BMO Capital Markets	Market Perform → Outperform	$46 → $48
Jan-22-24	Downgrade	Citigroup	Neutral → Sell
Dec-06-23	Upgrade	UBS	Neutral → Buy
Nov-10-23	Upgrade	Deutsche Bank	Hold → Buy
Nov-08-23	Upgrade	DNB Markets	Sell → Buy

Show Previous Ratings

Oct-14-26 04:07AM	Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda (PR Newswire)
Oct-06-26 12:46PM	European shares rise as retreating bond yields and oil prices boost risk appetite (Reuters)
12:39PM	Genmabs Lymphoma Bet Delivers a 51% Knockout (Moby)
11:42AM	Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial (BioPharma Dive)
03:52AM	Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk (Investing.com)
03:38AM	Loading…
03:38AM	European stocks rise 1% as French debt calms and ECBs Lane tempers hawks (Investing.com)
Oct-05-26 03:29PM	Genmab stock surges 11% on positive cancer drug trial data (Investing.com) +10.73%
02:54PM	AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (PR Newswire)
02:50PM	Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (Business Wire)
04:03AM	Genmab shares jump as ovarian cancer drug shows durable responses in trial (Investing.com)
Oct-03-26 03:40PM	Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Aug-07-26 12:43PM	Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook (GuruFocus.com)
Aug-06-26 07:20PM	Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:28PM	Genmab shares jump 8% after upbeat results prompt 2026 outlook raise (Investing.com)
Aug-05-26 09:18AM	Earnings To Watch: Genmab AS (GMAB) Q2 2026 -- GF Value Sees 47% Upside (GuruFocus.com)
04:00PM	Loading…
Jul-23-26 04:00PM	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Business Wire)
Jul-22-26 09:44AM	CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls (The Fly)
Jul-06-26 01:45PM	Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
Jun-29-26 04:15PM	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival (Business Wire) +5.57%
Jun-18-26 10:34AM	VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 (Exec Edge)
Jun-13-26 12:45PM	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (Business Wire)
Jun-11-26 10:45AM	Genmab Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients (Business Wire)
May-21-26 05:00PM	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress (Business Wire)
May-12-26 01:37PM	Junk-Rated Firms Rush to Reprice Risky Debt as Demand Surges (Bloomberg)
May-07-26 02:46PM	DARZALEX royalties drive Genmabs Q1 revenue higher amid expansion push (Investing.com)
May-06-26 09:17AM	What To Expect From Genmab AS (GMAB) Q1 2026 Earnings (GuruFocus.com)
Apr-22-26 06:14AM	Genmab gains as Goldman upgrades stock to Buy on increased pipeline confidence (Investing.com)
Apr-13-26 09:35AM	Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer (Business Wire)
Mar-27-26 09:46AM	Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls (The Fly)
Mar-02-26 09:53AM	Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
07:56AM	Loading…
07:56AM	Here Are Mondays Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More (24/7 Wall St.)
Feb-23-26 07:39AM	Novo Nordisk flags board members for re-election amid restructuring efforts (Pharmaceutical Technology)
Feb-20-26 12:39PM	These Are The 5 Best Stocks To Buy Now Or Watch (Investor's Business Daily)
04:10AM	Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales (Insider Monkey)
Feb-17-26 06:01PM	Genmab AS (GMAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions (GuruFocus.com)
01:46PM	Genmab A/S Q4 Earnings Call Highlights (MarketBeat)
Feb-16-26 07:15AM	Genmab AS (GMAB) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-13-26 08:58AM	Is the Options Market Predicting a Spike in Genmab Stock? (Zacks)
05:19AM	H.C. Wainwright Bullish on ?Genmab A/S (GMAB) on Robust Sales for DARZALEX (Insider Monkey)
Feb-10-26 08:32AM	Here's What Will Drive AbbVie's Top-line Growth in 2026 (Zacks)
06:41AM	Where is Genmab A/S (GMAB) Headed According to Wall Street? (Insider Monkey)
Feb-04-26 12:28PM	AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View (Zacks)
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
02:07AM	EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) (Insider Monkey)
Jan-22-26 02:16PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
12:21AM	Genmab (GMAB)'s Future Potential Underappreciated by Market (Insider Monkey)
Jan-20-26 01:36PM	Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside (Benzinga)
05:00AM	Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside (Insider Monkey)
Jan-16-26 01:31PM	Genmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Business Wire)
Jan-15-26 02:33PM	Genmab A/S (GMAB): A Bull Case Theory (Insider Monkey)
01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-13-26 02:20PM	Moderna Stock Gets Healthy Relative Strength Rating Jump (Investor's Business Daily)
Jan-07-26 09:00AM	Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence (Business Wire)
Dec-31-25 08:43AM	Here's Why Genmab A/S (GMAB) Rose in Q3 (Insider Monkey)
Dec-30-25 09:03AM	Genmab shelves Phase III lung cancer candidate (Pharmaceutical Technology)
08:20AM	Genmab to discontinue further development of acasunlimab (TipRanks)
Dec-29-25 08:12AM	Genmab Portfolio Prioritization Update (Business Wire)
Dec-26-25 01:48PM	Moderna Stock Sees Healthy Relative Strength Rating (Investor's Business Daily)
11:07AM	This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131% (Investor's Business Daily)
Dec-19-25 07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
Dec-16-25 02:09PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-15-25 02:59PM	Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Dec-12-25 01:36AM	Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period (Business Wire)
Dec-11-25 05:38PM	Dow Jones, Russell 2000 Hit Highs; Broadcom Sees AI Chip Sales Doubling (Investor's Business Daily)
Dec-10-25 12:40PM	ASH 2025: AbbVie and Genmabs Epkinly sets new standard in second-line FL (Clinical Trials Arena)
Dec-08-25 04:30PM	Genmab Announces New Data from Phase 1b/2 EPCORE CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) (Business Wire)
Dec-07-25 07:50AM	Genmab Presents Pivotal Phase 3 Data from EPCORE FL-1 Trial Demonstrating Clinical Benefit of EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma (Business Wire)
Dec-06-25 09:30AM	Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) (Business Wire)
08:00AM	AI Plays Lead Five Stocks To Watch Near Buy Points (Investor's Business Daily)
Dec-04-25 02:02PM	How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter (Investor's Business Daily)
Nov-21-25 02:37PM	Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street. (Investor's Business Daily)
Nov-18-25 02:19PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
11:30AM	Genmab Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-12-25 01:33PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
Nov-11-25 01:04PM	Syndax Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-06-25 06:05PM	Genmab AS (GMAB) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Nov-05-25 07:20AM	Genmab AS (GMAB) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-03-25 09:05AM	Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Oct-31-25 02:06PM	AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised (Zacks)
Oct-28-25 12:24PM	H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB) (Insider Monkey)
Oct-14-25 11:40AM	GMAB or TECH: Which Is the Better Value Stock Right Now? (Zacks)
Oct-10-25 12:19PM	Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. (Barrons.com)
Oct-06-25 09:50AM	GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal (Zacks)
Oct-03-25 05:29PM	Why Genmab Stock Popped on Friday (Motley Fool)
12:00PM	What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? (Zacks)
10:00AM	Best Momentum Stock to Buy for October 3rd (Zacks)
02:49AM	New Strong Buy Stocks for October 3rd (Zacks)
Sep-30-25 03:43PM	Why Genmab Stock Was Marching Higher Today (Motley Fool)
Sep-29-25 04:25PM	Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus (Investor's Business Daily)
07:36AM	This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired. (Barrons.com)
06:07AM	Premarket movers: Merus, GSK, Novo Nordisk (MarketWatch)
05:34AM	Months after cancer drug trial, Merus agrees to be bought at 41% premium (MarketWatch)
02:26AM	Genmab to Buy Cancer-Treatment Developer Merus For $8 Billion in Cash (The Wall Street Journal)
01:14AM	Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model (Business Wire)
Sep-17-25 02:27PM	Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB) (Insider Monkey)
Sep-11-25 11:14AM	Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S (Insider Monkey)
Sep-03-25 08:30AM	Genmab Announces Updated Results from Phase 2 EPCORE NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (Business Wire)
Aug-29-25 05:12AM	Genmab A/S (GMAB)'s Epcoritamab Delivers 95% Response in Lymphoma (Insider Monkey)
05:02AM	Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally (Insider Monkey)

Show Previous News

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Co-FounderDr. Jan G.J. van de Winkel Ph.D.

Executive VP & CFOMr. Anthony Pagano CPA

Executive VP & Chief Technical Operations OfficerMr. Rayne Waller

Executive VPMr. Gregory David Emil Mueller

Executive VP & Chief People OfficerMr. Christopher Cozic

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GMAB

Genmab ADR

Upgrade your Finviz experience